Download
the CAR T
discussion tool
This is more than hope.
This is remission.™
YESCARTA® is the first CAR T-cell therapy approved for adults with certain types of non-Hodgkin lymphoma. By empowering your immune system to recognize and destroy cancer cells, YESCARTA can give you a reason to hope when cancer returns or resists other treatments. YESCARTA may give you another chance for complete remission.
In a clinical study of 101 patients with non-Hodgkin lymphoma who had experienced other treatment failures, YESCARTA helped 51% [52 out of 101] of patients achieve complete remission and 21% [21 out of 101] of patients achieve partial remission.
YESCARTA® is the first CAR T-cell therapy approved for adults with certain types of non-Hodgkin lymphoma. By empowering your immune system to recognize and destroy cancer cells, YESCARTA can give you a reason to hope when cancer returns or resists other treatments. YESCARTA may give you another chance for complete remission.
In a clinical study of 101 patients with non-Hodgkin lymphoma who had experienced other treatment failures, YESCARTA helped 51% [52 out of 101] of patients achieve complete remission and 21% [21 out of 101] of patients achieve partial remission.
Don’t give up when treatments fail—my story proves it.
– Gary, a real
YESCARTA patient
Not all patients will experience the same results and side effects may vary.
HOW TO GET STARTED WHEN YOU’RE CONSIDERING YESCARTA
1
Download the CAR T Discussion Tool
This discussion guide provides questions you can ask your oncologist to better understand all of your treatment options. Review with your current oncologist, or an oncologist at an Authorized Treatment Center, to see if YESCARTA is an option for you.
2
Find an oncologist with YESCARTA experience
YESCARTA is available at Authorized Treatment Centers where medical staff is thoroughly trained and equipped to provide this type of therapy. Oncologists at Authorized Treatment Centers have the most experience with CAR T-cell therapy and are your most informed option for discussing YESCARTA.
